<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346826</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0181</org_study_id>
    <nct_id>NCT01346826</nct_id>
  </id_info>
  <brief_title>Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)</brief_title>
  <official_title>Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to test the hypothesis that the accelerated infusion of infliximab is not
      inferior to the conventional 2 hour infusion with respect to the frequency of infusion
      reaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard protocol of infliximab administration is the infusion for 2 hours. However, due
      to the discomfort of patients and limitation of medical resources, the accelerated infusion
      is more desirable if accelerated infusion does not increase the frequency of infusion
      reaction. Recent observational studies showed that the accelerated infusion of infliximab for
      1 hour or 30 minutes did not increase the frequency of infusion reaction if patients had not
      shown infusion reactions during previous 4 infusions for 2 hours. However, there are no
      randomized trials comparing the safety of accelerated infusion protocol and standard infusion
      protocol yet.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total numbers of infusion reactions related with infliximab infusion</measure>
    <time_frame>Within14 days after infliximab infusion</time_frame>
    <description>Total numbers of infusion reactions (including acute and delayed reactions) related with infliximab infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers of severe infusion reactions related with infliximab infusion</measure>
    <time_frame>Within14 days after infliximab infusion</time_frame>
    <description>Numbers of severe infusion reactions (Systolic blood pressure &lt; 80 mmHg with severe symptoms and signs necessiating stopping of infliximab infusion) related with infliximab infusion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>2 hours-infusion group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Number of patients: 57 (Standard 2 hours-infusion group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 hour-infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of patients: 59 (1 hour-infusion group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 minutes-infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of patients: 59 (30 minutes-infusion group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard 2 hours-infusion</intervention_name>
    <description>Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7.</description>
    <arm_group_label>2 hours-infusion group</arm_group_label>
    <other_name>Infliximab (Remicade, Centocor, Malvern, Philadelphia, PA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Accelerated 1 hour-infusion</intervention_name>
    <description>Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7.</description>
    <arm_group_label>1 hour-infusion group</arm_group_label>
    <other_name>Infliximab (Remicade, Centocor, Malvern, Philadelphia, PA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Accelerated 30 minutes-infusion</intervention_name>
    <description>Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5.</description>
    <arm_group_label>30 minutes-infusion group</arm_group_label>
    <other_name>Infliximab (Remicade, Centocor, Malvern, Philadelphia, PA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving infliximab for Crohn's disease or ulcerative colitis

          -  Ethnicity: Korean

          -  Patients who did not show any infusion reactions during 4 times of infliximab (5mg/kg)
             infusions for 2 hours

          -  Informed consents

        Exclusion Criteria:

          -  Sever cardiopulmonary diseases

          -  Allergic diseases

               -  Bronchial asthma

               -  Allergic rhinitis

               -  Atopic dermatitis

               -  Other allergic diseases determined not suitable for study participation by
                  investigators

          -  Severe liver disease

          -  Severe renal disease

          -  Body weight over 100 kg

          -  Other medical or surgical disease determined not suitable for study participation by
             investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suk-Kyun Yang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009 Jan;21(1):71-5. doi: 10.1097/MEG.0b013e3283081afe.</citation>
    <PMID>19060632</PMID>
  </reference>
  <reference>
    <citation>Van Assche G, Vermeire S, Noman M, Amant C, Weyts E, Vleminckx A, Vermeyen MJ, Rutgeerts P. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohns Colitis. 2010 Sep;4(3):329-33. doi: 10.1016/j.crohns.2009.12.012. Epub 2010 Jan 18.</citation>
    <PMID>21122522</PMID>
  </reference>
  <reference>
    <citation>Bhat S, Sharma D, Doherty P, Tham TC, Caddy GR. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis. 2010 Nov;16(11):1922-5. doi: 10.1002/ibd.21279.</citation>
    <PMID>20848465</PMID>
  </reference>
  <reference>
    <citation>Breynaert C, Ferrante M, Fidder H, Van Steen K, Noman M, Ballet V, Vermeire S, Rutgeerts P, Van Assche G. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol. 2011 Apr;106(4):778-85. doi: 10.1038/ajg.2011.61. Epub 2011 Mar 15.</citation>
    <PMID>21407184</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Suk-Kyun Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Infusion reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

